Lisa A. Raedler, PhD, RPh, Medical Writer

Authored Items

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Melanoma

Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Lymphoma

Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in Drug Updates, FDA Updates, Gastrointestinal Cancers

Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Leukemia

Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Lymphoma

Infugem (Gemcitabine) First Formulation of Premixed, Ready-to-Administer Intravenous Chemotherapy Approved for Several Tumor Types

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates

Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in Drug Updates, FDA Updates, Leukemia

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in Breast Cancer, Drug Updates, FDA Updates

Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Leukemia

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in Drug Updates, FDA Updates

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals in Drug Updates, FDA Updates

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Lung Cancer

Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Lymphoma

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Lymphoma

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Bladder Cancer

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Breast Cancer

Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Multiple Myeloma

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Bladder Cancer

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Leukemia

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Ovarian Cancer

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma

Lisa A. Raedler, PhD, RPh, Medical Writer

TOP - November 2017, Vol 10, No 4 in Drug Updates

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh, Medical Writer

2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh, Medical Writer

2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles

Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles

Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)

Lisa A. Raedler, PhD, RPh, Medical Writer

Patient Assistance Profiler December 2016

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

Web Exclusives in Drug Updates

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

TOP - August 2016, Vol 9, No 3 in Drug Updates

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas

Lisa A. Raedler, PhD, RPh, Medical Writer

2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles

Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh, Medical Writer

TOP - February 2016, Vol 9, No 1 in Drug Updates

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

TOP November 2015 Vol 8 No 4 in Drug Updates

Highlights from Key Meetings in Hematology and Oncology

Brian Dinh, PharmD, Lisa A. Raedler, PhD, RPh, Medical Writer

TOP-Resident Reporter-September 2013

Highlights from Key Meetings in Hematology and Oncology

Brian Dinh, PharmD, Lisa A. Raedler, PhD, RPh, Medical Writer

Resident Reporter-September 2013